Nasopharyngeal Cancer - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 194 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nasopharyngeal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Nasopharyngeal Cancer - Pipeline Review, H2 2016', provides an overview of the Nasopharyngeal Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer
- The report reviews pipeline therapeutics for Nasopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Nasopharyngeal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Nasopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Nasopharyngeal Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Nasopharyngeal Cancer - Overview 12
Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis 13
Nasopharyngeal Cancer - Therapeutics under Development by Companies 14
Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 16
Nasopharyngeal Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Nasopharyngeal Cancer - Products under Development by Companies 20
Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes 22
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 23
Advenchen Laboratories, LLC 23
Ambrx, Inc. 24
arGEN-X BV 25
Atara Biotherapeutics, Inc. 26
AVEO Pharmaceuticals, Inc. 27
Betta Pharmaceuticals Co. Ltd. 28
BioDiem Ltd 29
Biomics Biotechnologies Co., Ltd. 30
Celgene Corporation 31
Cell Medica Limited 32
F. Hoffmann-La Roche Ltd. 33
GlaxoSmithKline Plc 34
Lakewood-Amedex Inc 35
Merck & Co., Inc. 36
Merck KGaA 37
Molecular Partners AG 38
Novartis AG 39
Ono Pharmaceutical Co., Ltd. 40
Pharmacyclics, Inc. 41
Sapvax 42
Tessa Therapeutics Pte Ltd 43
Theravectys SA 44
Nasopharyngeal Cancer - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
abexinostat hydrochloride - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
apatinib - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
ARGX-110 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
atezolizumab - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
avelumab - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
azacitidine - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
baltaleucel-T - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Cellular Immunotherapy for Multiple Sclerosis - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Cellular Immunotherapy for Oncology - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Cellular Immunotherapy for Oncology - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Cellular Immunotherapy for Solid Tumor and Central Nervous System Disorders - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
DC-120 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
EBV-nRNA - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Epstein-Barr virus vaccine - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
ficlatuzumab - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
GSK-2849330 - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
icotinib hydrochloride - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
JS-001 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
LAG-525 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
MP-0250 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
MVA vaccine - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
NEO-212 - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
nimotuzumab - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
nivolumab - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
PDR-001 - Drug Profile 147
Product Description 147
Mechanism Of Action 147
R&D Progress 147
pembrolizumab - Drug Profile 148
Product Description 148
Mechanism Of Action 148
R&D Progress 148
RO-5203280 - Drug Profile 178
Product Description 178
Mechanism Of Action 178
R&D Progress 178
Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile 179
Product Description 179
Mechanism Of Action 179
R&D Progress 179
SV-638 - Drug Profile 180
Product Description 180
Mechanism Of Action 180
R&D Progress 180
TT-10 - Drug Profile 181
Product Description 181
Mechanism Of Action 181
R&D Progress 181
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 182
Product Description 182
Mechanism Of Action 182
R&D Progress 182
Vaccine for Oncology - Drug Profile 183
Product Description 183
Mechanism Of Action 183
R&D Progress 183
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 184
Product Description 184
Mechanism Of Action 184
R&D Progress 184
Nasopharyngeal Cancer - Dormant Projects 185
Nasopharyngeal Cancer - Discontinued Products 186
Nasopharyngeal Cancer - Product Development Milestones 187
Featured News & Press Releases 187
Jun 23, 2016: Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) 187
Jun 06, 2016: Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate 187
May 18, 2016: Atara Bio Announces Presentation of Clinical Data from EBV-CT Product Candidate at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 188
Apr 19, 2016: Atara Biotherapeutics Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor 188
Mar 16, 2016: Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research Annual Meeting 189
Sep 26, 2015: New Findings Show Anti-Tumor Activity of KEYTRUDA in Patients with Advanced Nasopharyngeal Carcinoma 190
Sep 10, 2015: U.S. FDA grants Fast Track Designation to Tessa Therapeutics' TT10 EB-VST for the treatment of Head and Neck Cancers 191
Mar 27, 2015: U.S. FDA approves Tessa Therapeutic's IND application to begin Phase III trial involving Adoptive T cell therapy on Nasopharyngeal Cancer 191
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 191
Appendix 193
Methodology 193
Coverage 193
Secondary Research 193
Primary Research 193
Expert Panel Validation 193
Contact Us 193
Disclaimer 194

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, H2 2016 12
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 23
Nasopharyngeal Cancer - Pipeline by Ambrx, Inc., H2 2016 24
Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H2 2016 25
Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016 26
Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 27
Nasopharyngeal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 28
Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H2 2016 29
Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 30
Nasopharyngeal Cancer - Pipeline by Celgene Corporation, H2 2016 31
Nasopharyngeal Cancer - Pipeline by Cell Medica Limited, H2 2016 32
Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 33
Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 34
Nasopharyngeal Cancer - Pipeline by Lakewood-Amedex Inc, H2 2016 35
Nasopharyngeal Cancer - Pipeline by Merck & Co., Inc., H2 2016 36
Nasopharyngeal Cancer - Pipeline by Merck KGaA, H2 2016 37
Nasopharyngeal Cancer - Pipeline by Molecular Partners AG, H2 2016 38
Nasopharyngeal Cancer - Pipeline by Novartis AG, H2 2016 39
Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 40
Nasopharyngeal Cancer - Pipeline by Pharmacyclics, Inc., H2 2016 41
Nasopharyngeal Cancer - Pipeline by Sapvax, H2 2016 42
Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 43
Nasopharyngeal Cancer - Pipeline by Theravectys SA, H2 2016 44
Assessment by Monotherapy Products, H2 2016 45
Number of Products by Stage and Target, H2 2016 47
Number of Products by Stage and Mechanism of Action, H2 2016 49
Number of Products by Stage and Route of Administration, H2 2016 51
Number of Products by Stage and Molecule Type, H2 2016 53
Nasopharyngeal Cancer - Dormant Projects, H2 2016 185
Nasopharyngeal Cancer - Discontinued Products, H2 2016 186